U.S. Software Stock News

NYSE:JXN
NYSE:JXNDiversified Financial

Jackson Financial (JXN): Revisiting Valuation After Strong Multi‑Year Shareholder Returns

Jackson Financial (JXN) has quietly put up solid numbers, with annual revenue and net income both growing around 9% and 14%. That kind of steady progress is starting to draw more valuation-focused attention. See our latest analysis for Jackson Financial. The stock has backed that earnings momentum with a strong 30 day share price return of 14.66 percent and an impressive three year total shareholder return of 252.93 percent, suggesting momentum is still firmly on Jackson Financial's side. If...
NYSE:PERF
NYSE:PERFSoftware

How Perfect’s AI Beauty APIs and Developer Pivot Could Reframe the Long-Term Case for PERF Investors

In December 2025, Perfect Corp. announced it will showcase a new generation of AI beauty agents and a modular, consumption-based API suite at CES 2026, aimed at powering personalized, cross-channel experiences for brands of all sizes. The move signals a push to become an infrastructure provider for beauty and retail AI, shifting from standalone apps toward developer-first tools that can embed Perfect’s technology across e-commerce, mobile, and in-store journeys. We’ll now examine how...
NYSE:TBBB
NYSE:TBBBConsumer Retailing

Assessing BBB Foods (NYSE:TBBB) Valuation After Strong Sales Beat and Rapid Expansion Momentum

BBB Foods (NYSE:TBBB) just posted quarterly results that turned heads, with sales jumping 37% and EBITDA margins near the top of expectations, supported by rapid store expansion and standout same store growth. See our latest analysis for BBB Foods. The strong quarter seems to be feeding into the narrative, with a 90 day share price return of 35.68 percent and year to date share price gains of 18.34 percent. This suggests momentum is clearly building off these growth signals. If this kind of...
NasdaqGM:RAPT
NasdaqGM:RAPTBiotechs

RAPT Therapeutics (RAPT): Evaluating Its Rich Valuation After TD Cowen’s Bullish Initiation and Phase 2 Progress

RAPT Therapeutics (RAPT) has been back on traders’ screens after TD Cowen kicked off coverage with a positive stance, following upbeat Phase 2 data for ozureprubart and fresh FDA clearance for a Phase 2b food allergy trial. See our latest analysis for RAPT Therapeutics. That backdrop has helped fuel a sharp re-rating, with the stock delivering a 179.68 percent year to date share price return and a 162 percent one year total shareholder return, even as the five year total shareholder return...
NasdaqCM:CDRO
NasdaqCM:CDROHospitality

Codere Online (NasdaqCM:CDRO) One-Off Gain-Driven Profit Challenges Bullish Earnings Narrative

Codere Online Luxembourg (NasdaqCM:CDRO) has reported its H1 2025 results with total revenue of about €203.9 million over the trailing twelve months and basic EPS of €0.02, supported by net income of just over €1.0 million. The company has seen revenue move from €189.1 million to €203.9 million on a trailing twelve month basis, while EPS has shifted from a loss of €0.05 to a modest profit of €0.02. This highlights how small changes in profitability can meaningfully affect margins in this kind...
NYSE:CUBI
NYSE:CUBIBanks

Does Customers Bancorp’s 62.5% 2025 Rally Still Leave Room for Investors?

Wondering if Customers Bancorp is still worth buying after its big run, or if most of the upside is already priced in? You are not alone. The stock has climbed 4.9% over the last week, 16.9% in the past month, and is now up an impressive 62.5% year to date, building on multi year gains of 60.5% over 1 year, 172.9% over 3 years, and 323.9% over 5 years. These moves have come alongside a shift in market sentiment toward regional banks, as investors have grown more comfortable with funding and...